TFTracy L. Fetterly

Tracy L. Fetterly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tracy L. Fetterly has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Danny G. Winder

    Department of Neurobiology, UMass Chan Medical School, Worcester, MA, USA.

    4 shared publications
  • Bruno Marchand

    Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA

    2 shared publications
  • Eleftherios Michailidis

    Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA

    2 shared publications
  • Kamalendra Singh

    Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA

    2 shared publications
  • Karen A. Kirby

    Center For ViroScience and Cure Laboratory of Biochemical Pharmacology Department of Pediatrics Emory University School of Medicine Children's Healthcare of Atlanta Atlanta Georgia USA

    2 shared publications
  • Maxwell D. Leslie

    Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA

    2 shared publications

Latest Publications

  • Open Access

    α2A-Adrenergic Receptor Activation Decreases Parabrachial Nucleus Excitatory Drive onto BNST CRF Neurons and Reduces Their ActivityIn Vivo

    by Tracy L. Fetterly, Aakash Basu, Brett P. Nabit, Elias Awad, Kellie M. Williford, Samuel W. Centanni, Robert T. Matthews, Yuval Silberman, Danny G. Winder

    Stress contributes to numerous psychiatric disorders. Corticotropin releasing factor (CRF) signaling and CRF neurons in the bed nucleus of the stria terminalis (BNST) drive negative affective behaviors, thus agents that decrease activity of these cells may be of therapeutic interest. Here, we show that acute restraint stress increases cFos expression in CRF neurons in the mouse dorsal BNST, consistent with a role for these neurons in stress-related behaviors. We find that activation of α2A-adrenergic receptors (ARs) by the agonist guanfacine reduced cFos expression in these neurons both in stressed and unstressed conditions. Further, we find that α- and β-ARs differentially regulate excitatory drive onto these neurons. Pharmacological and channelrhodopsin-assisted mapping experiments suggest that α2A-ARs specifically reduce excitatory drive from parabrachial nucleus (PBN) afferents onto CRF neurons. Given that the α2A-AR is a Gi-linked GPCR, we assessed the impact of activating the Gi-coupled DREADD hM4Di in the PBN on restraint stress regulation of BNST CRF neurons. CNO activation of PBN hM4Di reduced stress-inducedFosin BNSTCrhneurons. Further, usingPrkcdas an additional marker of BNST neuronal identity, we uncovered a female-specific upregulation of the coexpression ofPrkcd/Crhin BNST neurons following stress, which was prevented by ovariectomy. These findings show that stress activates BNST CRF neurons, and that α2A-AR activation suppresses thein vivoactivity of these cells, at least in part by suppressing excitatory drive from PBN inputs onto CRF neurons.SIGNIFICANCE STATEMENTStress is a major variable contributing to mood disorders. Here, we show that stress increases activation of BNST CRF neurons that drive negative affective behavior. We find that the clinically well tolerated α2A-AR agonist guanfacine reduces activity of these cellsin vivo, and reduces excitatory PBN inputs onto these cellsex vivo. Additionally, we uncover a novel sex-dependent coexpression ofPrkcdwithCrhin female BNST neurons after stress, an effect abolished by ovariectomy. These results demonstrate input-specific interactions between norepinephrine and CRF, and point to an action by which guanfacine may reduce negative affective responses.


  • Endocannabinoid control of the insular-bed nucleus of the stria terminalis circuit regulates negative affective behavior associated with alcohol abstinence

    by Samuel W. Centanni, Bridget D. Morris, Joseph R. Luchsinger, Gaurav Bedse, Tracy L. Fetterly, Sachin Patel, Danny G. Winder

    Negative affect is a core symptom domain associated with an array of neurological and psychiatric disorders and is only partially targeted by current therapies, highlighting the need for better, more targeted treatment options. This study focuses on negative affective symptoms associated with prolonged alcohol abstinence, one of the leading causes of relapse. Using a mouse model of chronic alcohol consumption followed by forced abstinence (CDFA), prolonged alcohol abstinence increased c-fos expression and spontaneous glutamatergic neurotransmission in the dorsal bed nucleus of the stria terminalis (dBNST), a region heavily implicated in negative affect in both humans and rodents. Further, pharmacologically enhancing eCBs with JZL184 prevents abstinence-induced increases in dBNST neuronal activity, underscoring the therapeutic potential of drugs targeting the brain’s eCB system. Next, we used a channelrhodopsin-assisted mapping strategy to identify excitatory inputs to the dBNST that could contribute to CDFA-induced negative affect. We identified the insular cortex (insula), a region involved in regulating interoception, as a dense, functional, endocannabinoid-sensitive input to the dBNST. Using a chemogenetic strategy to locally mimic eCB signaling, we demonstrate that the insula strongly influences CDFA behavioral and BNST neuronal activity. Lastly, we used viral anterograde transsynaptic expression in combination with a Gq-DREADD to selectively recruit dBNST neurons receiving insula projections. Chemogenetic recruitment of these neurons mimicked behavioral and c-fos responses observed in CDFA. Collectively, this study supports a role for the insula-BNST neural circuit in negative affective disturbances and highlights the therapeutic potential of the endocannabinoid system for treating negative affective disorders.


  • The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

    by Matthew B. Pomrenze, Tracy L. Fetterly, Danny G. Winder, Robert O. Messing

    Corticotropin releasing factor (CRF) is a neuropeptide that plays a key role in behavioral and physiological responses to stress. A large body of animal literature implicates CRF acting at type 1 CRF receptors (CRFR1) in consumption by alcohol‐dependent subjects, stress‐induced reinstatement of alcohol seeking, and possibly binge alcohol consumption. These studies have encouraged recent pilot studies of CRFR1 antagonists in humans with alcohol use disorder (AUD). It was a great disappointment to many in the field that these studies failed to show an effect of these compounds on stress‐induced alcohol craving. Here, we examine these studies to explore potential limitations and discuss preclinical and human literature to ask whether CRFR1 is still a valid drug target to pursue for the treatment of AUD.


  • Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking

    by Katherine M Holleran, Hadley H Wilson, Tracy L Fetterly, Rebecca J Bluett, Samuel W Centanni, Rachel A Gilfarb, Lauren E R Rocco, Sachin Patel, Danny G Winder

    Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology, publishing the highest quality original research and advancing our understanding of the brain and behavior.


  • Ethanol Produces Corticotropin‐Releasing Factor Receptor‐Dependent Enhancement of Spontaneous Glutamatergic Transmission in the Mouse Central Amygdala

    by Yuval Silberman, Tracy L. Fetterly, Elias K. Awad, Elana J. Milano, Ted B. Usdin, Danny G. Winder

    Background: Ethanol (EtOH) modulation of central amygdala (CeA) neurocircuitry plays a key role in the development of alcoholism via activation of the corticotropin‐releasing factor (CRF) receptor (CRFR) system. Previous work has predominantly focused on EtOH × CRF interactions on the CeA GABA circuitry; however, our laboratory recently showed that CRF enhances CeA glutamatergic transmission. Therefore, this study sought to determine whether EtOH modulates CeA glutamate transmission via activation of CRF signaling.Methods: The effects of EtOH on spontaneous excitatory postsynaptic currents (sEPSCs) and basal resting membrane potentials were examined via standard electrophysiology methods in adult male C57BL/6J mice. Local ablation of CeA CRF neurons (CRFCeAhDTR) was achieved by targeting the human diphtheria toxin receptor (hDTR) to CeA CRF neurons with an adeno‐associated virus. Ablation was quantified post hoc with confocal microscopy. Genetic targeting of the diphtheria toxin active subunit to CRF neurons (CRFDTA mice) ablated CRF neurons throughout the central nervous system, as assessed by quantitative reverse transcriptase polymerase chain reaction quantification of CRF mRNA.Results: Acute bath application of EtOH significantly increased sEPSC frequency in a concentration‐dependent manner in CeA neurons, and this effect was blocked by pretreatment of co‐applied CRFR1 and CRFR2 antagonists. In experiments utilizing a CRF‐tomato reporter mouse, EtOH did not significantly alter the basal membrane potential of CeA CRF neurons. The ability of EtOH to enhance CeA sEPSC frequency was not altered in CRFCeAhDTR mice despite a ~78% reduction in CeA CRF cell counts. The ability of EtOH to enhance CeA sEPSC frequency was also not altered in the CRFDTA mice despite a 3‐fold reduction in CRF mRNA levels.Conclusions: These findings demonstrate that EtOH enhances spontaneous glutamatergic transmission in the CeA via a CRFR‐dependent mechanism. Surprisingly, our data suggest that this action may not require endogenous CRF.


  • Open Access

    Effects of Substitutions at the 4′ and 2 Positions on the Bioactivity of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine

    by Karen A. Kirby, Eleftherios Michailidis, Tracy L. Fetterly, Musetta A. Steinbach, Kamalendra Singh, Bruno Marchand, Maxwell D. Leslie, Ariel N. Hagedorn, Eiichi N. Kodama, Victor E. Marquez, et al.

    Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) form the backbone of most anti-HIV therapies. We have shown that 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) is a highly effective NRTI; however, the reasons for the potent antiviral activity of EFdA are not well understood. Here, we use a combination of structural, computational, and biochemical approaches to examine how substitutions in the sugar or adenine rings affect the incorporation of dA-based NRTIs like EFdA into DNA by HIV RT and their susceptibility to deamination by adenosine deaminase (ADA). Nuclear magnetic resonance (NMR) spectroscopy studies of 4′-substituted NRTIs show that ethynyl or cyano groups stabilize the sugar ring in the C-2′-exo/C-3′-endo (north) conformation. Steady-state kinetic analysis of the incorporation of 4′-substituted NRTIs by RT reveals a correlation between the north conformation of the NRTI sugar ring and efficiency of incorporation into the nascent DNA strand. Structural analysis and the kinetics of deamination by ADA demonstrate that 4′-ethynyl and cyano substitutions decrease the susceptibility of adenosine-based compounds to ADA through steric interactions at the active site. However, the major determinant for decreased susceptibility to ADA is the 2-halo substitution, which alters the pK a of N1 on the adenine base. These results provide insight into how NRTI structural attributes affect their antiviral activities through their interactions with the RT and ADA active sites.


  • Open Access

    Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase

    by Karen A. Kirby, Bruno Marchand, Yee Tsuey Ong, Tanyaradzwa P. Ndongwe, Atsuko Hachiya, Eleftherios Michailidis, Maxwell D. Leslie, Daniel V. Sietsema, Tracy L. Fetterly, Christopher A. Dorst, et al.

    RNase H inhibitors (RNHIs) have gained attention as potential HIV-1 therapeutics. Although several RNHIs have been studied in the context of HIV-1 reverse transcriptase (RT) RNase H, there is no information on inhibitors that might affect the RNase H activity of other RTs. We performed biochemical, virological, crystallographic, and molecular modeling studies to compare the RNase H function and inhibition profiles of the gammaretroviral xenotropic murine leukemia virus-related virus (XMRV) and Moloney murine leukemia virus (MoMLV) RTs to those of HIV-1 RT. The RNase H activity of XMRV RT is significantly lower than that of HIV-1 RT and comparable to that of MoMLV RT. XMRV and MoMLV, but not HIV-1 RT, had optimal RNase H activities in the presence of Mn 2+ and not Mg 2+ . Using hydroxyl-radical footprinting assays, we demonstrated that the distance between the polymerase and RNase H domains in the MoMLV and XMRV RTs is longer than that in the HIV-1 RT by ∼3.4 Å. We identified one naphthyridinone and one hydroxyisoquinolinedione as potent inhibitors of HIV-1 and XMRV RT RNases H with 50% inhibitory concentrations ranging from ∼0.8 to 0.02 μM. Two acylhydrazones effective against HIV-1 RT RNase H were less potent against the XMRV enzyme. We also solved the crystal structure of an XMRV RNase H fragment at high resolution (1.5 Å) and determined the molecular details of the XMRV RNase H active site, thus providing a framework that would be useful for the design of antivirals that target RNase H.